Combat Medical, a medical device company optimising the delivery and efficacy of cancer therapeutics, has raised £2.6 million in the first close of a Series A financing led by T&J Meyer Family Foundation, with participation from Varia Ventures, NW Angel Fund and non-institutional family offices and individuals. The funding will advance its hyperthermic intravesical chemotherapy treatment, HIVEC, through phase 3 clinical trials and toward FDA registration.
The financing will be used to further fund the ongoing pivotal FDA registration trial, HIVEC HEAT, which is investigating the effectiveness of HIVEC in treating BCG unresponsive non-muscle-invasive bladder cancer. The primary objective is to generate phase 3 clinical data to evidence HIVEC as an effective, safe and tolerable alternative to the current standard of care, radical cystectomy.
Future financings will be used to complete FDA registration and grow operations to scale. Plans also include expanding existing clinical programmes for advanced bladder cancer through HIVEC and peritoneal cancer through HIPEC, with a focus on US market entry.
Combat Medical reports an installed base of more than 350 systems and over 100,000 HIVEC treatments completed to date. The treatment is positioned as a bladder-sparing alternative for patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
Our installed base of over 350 systems and the completion of over 100,000 HIVEC treatments to date demonstrates efficacy and use as a safe and well-tolerated, bladder-sparing alternative to radical cystectomy in BCG-unresponsive, high-risk NMIBC. Setting a new standard for patient care, it also provides clinicians and payers with advanced, affordable options that can easily be built into current treatment pathways. We are proud to have our investors on board as we progress through to FDA approval.
